Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial
Aditi Sinha, Arvind Bagga(All India Institute of Medical Sciences), Pragya Goyal(Indian Council of Medical Research), Mani Kalaivani(All India Institute of Medical Sciences), Mamta Puraswani(All India Institute of Medical Sciences), Pankaj Hari(Indian Council of Medical Research)
Cited by 59
Related Papers
Patients with Mutations in NPHS2 (Podocin) Do Not Respond to Standard Steroid Treatment of Nephrotic Syndrome
|Journal of the American Society of Nephrology|2004|415
Clinical Features of Anti-Factor H Autoantibody–Associated Hemolytic Uremic Syndrome
|Journal of the American Society of Nephrology|2010|296
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|256
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children
|Kidney International|2013|216
Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome
|Clinical Journal of the American Society of Nephrology|2010|203